Wall Street brokerages expect that DBV TECHNOLOGIE/S (NASDAQ:DBVT) will report earnings per share of ($0.68) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for DBV TECHNOLOGIE/S’s earnings. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that DBV TECHNOLOGIE/S will report full year earnings of ($2.59) per share for the current year, with EPS estimates ranging from ($3.33) to ($2.27). For the next year, analysts expect that the business will report earnings of ($2.15) per share, with EPS estimates ranging from ($2.76) to ($1.40). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow DBV TECHNOLOGIE/S.
DBVT has been the subject of a number of analyst reports. Zacks Investment Research cut DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a report on Friday, April 12th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $10.00 target price on shares of DBV TECHNOLOGIE/S in a report on Wednesday, March 6th. JMP Securities reaffirmed a “buy” rating and issued a $20.00 target price on shares of DBV TECHNOLOGIE/S in a report on Wednesday, March 6th. BidaskClub downgraded DBV TECHNOLOGIE/S from a “hold” rating to a “sell” rating in a report on Wednesday, March 27th. Finally, ValuEngine downgraded DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $14.78.
Shares of DBVT stock traded up $0.42 on Friday, hitting $9.97. 20,472 shares of the stock traded hands, compared to its average volume of 372,259. The company has a market capitalization of $567.62 million, a price-to-earnings ratio of -2.97 and a beta of 1.97. DBV TECHNOLOGIE/S has a 52 week low of $3.60 and a 52 week high of $25.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.34 and a quick ratio of 3.30.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Story: Mutual Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.